The Straits Trading Company Limited (SGX:S20)
Singapore · Delayed Price · Currency is SGD | Market Cap | 773.65M |
| Revenue (ttm) | 595.23M |
| Net Income (ttm) | -7.23M |
| Shares Out | 468.88M |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | 0.08 (4.91%) |
| Ex-Dividend Date | May 8, 2025 |
| Volume | 615,600 |
| Average Volume | 248,505 |
| Open | 1.590 |
| Previous Close | 1.650 |
| Day's Range | 1.560 - 1.600 |
| 52-Week Range | 1.250 - 1.780 |
| Beta | 0.56 |
| RSI | 45.52 |
| Earnings Date | Aug 11, 2025 |
About Revance Therapeutics
The Straits Trading Company Limited, a conglomerate-investment company, engages in the resources, property, and hospitality businesses. The company operates in four segments: Resources, Real Estate, Hospitality, and Others. It engages in the smelting of tin concentrates and tin bearing materials. The company also produces and sells various grades of refined tin metal and by-products; and invests in other metals and mineral resources. In addition, it invests in, develops, leases, and sells real estate properties; provides property and real estat... [Read more]
Financial Performance
In 2024, SGX:S20's revenue was 595.23 million, an increase of 7.17% compared to the previous year's 555.42 million. Losses were -7.23 million, -74.71% less than in 2023.
Financial StatementsNews
How an 'accidental businesswoman' transformed one of Singapore's oldest companies into a real estate powerhouse
CNBC Managing Asia's Christine Tan speaks to Straits Trading's Executive Chairman Chew Gek Khim, and finds out how under her leadership she transformed one of Singapore's oldest companies into a real ...